Author Index: K
• ORAL ABSTRACTS: DIAGNOSIS
• ASSESSING CVD RISK AND BURDEN: DIFFERENCES IN PREDICTION MODELS AND POPULATIONS
• THE COST OF BEING WRONG: THE IMPACT OF PREDICTION UNCERTAINTY ON THE COST-EFFECTIVENESS OF RISK-STRATIFIED STRATEGIES
• FROM PREDICTED RISK TO PREDICTED BURDEN OF CARDIOVASCULAR DISEASE
• RETHINKING METHODS TO IDENTIFY OPTIMAL TREATMENT AND DIAGNOSTIC THRESHOLDS: EVALUATING RISK-BASED OUTCOMES IN CORONARY HEART DISEASE
• DECISION MAKING AND VALUE OF INFORMATION ANALYSIS IN A REAL-WORLD MULTI-CRITERIA CONTEXT
• ESTIMATING THE COST-EFFECTIVENESS OF USING CIRCULATING TUMOR CELL DETECTION TO GUIDE SYSTEMIC THERAPY IN STAGE IA PRIMARY BREAST CANCER
• THE COST-EFFECTIVENESS OF POINT-OF-CARE TROPONIN TESTING TO DIAGNOSE ACUTE CORONARY SYNDROME IN PRIMARY CARE
• ASSESSING CVD RISK AND BURDEN: DIFFERENCES IN PREDICTION MODELS AND POPULATIONS
• THE COST OF BEING WRONG: THE IMPACT OF PREDICTION UNCERTAINTY ON THE COST-EFFECTIVENESS OF RISK-STRATIFIED STRATEGIES
• FROM PREDICTED RISK TO PREDICTED BURDEN OF CARDIOVASCULAR DISEASE
• RETHINKING METHODS TO IDENTIFY OPTIMAL TREATMENT AND DIAGNOSTIC THRESHOLDS: EVALUATING RISK-BASED OUTCOMES IN CORONARY HEART DISEASE
• DECISION MAKING AND VALUE OF INFORMATION ANALYSIS IN A REAL-WORLD MULTI-CRITERIA CONTEXT
• ESTIMATING THE COST-EFFECTIVENESS OF USING CIRCULATING TUMOR CELL DETECTION TO GUIDE SYSTEMIC THERAPY IN STAGE IA PRIMARY BREAST CANCER
• THE COST-EFFECTIVENESS OF POINT-OF-CARE TROPONIN TESTING TO DIAGNOSE ACUTE CORONARY SYNDROME IN PRIMARY CARE
• MIXED METHOD PROGRAM EVALUATION OF THE TELEHOMECARE PROGRAM FOR PATIENTS WITH HEART FAILURE (HF) AND CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) IN ONTARIO, CANADA: QUALITATIVE STUDY
• THE ROLE OF TELEHOMECARE ON BLOOD PRESSURE CONTROL IN PATIENTS WITH HEART FAILURE AND CHRONIC OBSTRUCTIVE PULMONARY DISEASE IN ONTARIO, CANADA
• THE BENEFIT-HARM BALANCE OF PROSTATE CANCER SCREENING IN MEN WITH AVERAGE AND ELEVATED FAMILIAL RISK – PREDICTIONS OF THE ONCOTYROL PROSTATE CANCER OUTCOME AND POLICY MODEL
• NEW MODEL OF HEALTHCARE DELIVERY: TELEHOMECARE PROGRAM FOR HEART FAILURE (HF) AND CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) PATIENTS IN ONTARIO, CANADA
• DIAGNOSTIC ACCURACY OF LEVEL IV PORTABLE SLEEP TESTS VERSUS POLYSOMNOGRAPHY FOR SLEEP-DISORDERED BREATHING: A SYSTEMATIC REVIEW AND META-ANALYSIS
• THE ROLE OF TELEHOMECARE ON BLOOD PRESSURE CONTROL IN PATIENTS WITH HEART FAILURE AND CHRONIC OBSTRUCTIVE PULMONARY DISEASE IN ONTARIO, CANADA
• THE BENEFIT-HARM BALANCE OF PROSTATE CANCER SCREENING IN MEN WITH AVERAGE AND ELEVATED FAMILIAL RISK – PREDICTIONS OF THE ONCOTYROL PROSTATE CANCER OUTCOME AND POLICY MODEL
• NEW MODEL OF HEALTHCARE DELIVERY: TELEHOMECARE PROGRAM FOR HEART FAILURE (HF) AND CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) PATIENTS IN ONTARIO, CANADA
• DIAGNOSTIC ACCURACY OF LEVEL IV PORTABLE SLEEP TESTS VERSUS POLYSOMNOGRAPHY FOR SLEEP-DISORDERED BREATHING: A SYSTEMATIC REVIEW AND META-ANALYSIS
• LONG-TERM EFFECTIVENESS AND COST EFFECTIVENESS OF DIFFERENT ANTIVIRAL TREATMENTS FOR CHRONIC GENOTYPE-1 HCV INFECTION IN GERMANY INCLUDING OMBITASVIR/PARITAPREVIR/RITONAVIR AND DASABUVIR
• DIRECT ANTIVIRAL DRUGS FOR THE TREATMENT OF CHRONIC HEPATITIS C PATIENTS WITH GENOTYPE 1 OR 4 IN FRANCE - COST-EFFECTIVENESS OF OMBITASVIR/PARITAPREVIR/RITONAVIR WITH OR WITHOUT DASABUVIR BY FIBROSIS SUBGROUP
• DIRECT ANTIVIRAL DRUGS FOR THE TREATMENT OF CHRONIC HEPATITIS C PATIENTS WITH GENOTYPE 1 OR 4 IN FRANCE - COST-EFFECTIVENESS OF OMBITASVIR/PARITAPREVIR/RITONAVIR WITH OR WITHOUT DASABUVIR BY FIBROSIS SUBGROUP